Mingzhi Healthcare Completes Tens of Millions RMB Series A Financing to Accelerate Oncology Data Application Service Platform Development
Wise Healthcare Announces Completion of Tens of Millions of RMB in Series A Financing to Advance Its Oncology Database Service Platform and Digital Health Product PipelineRecently, Wise Healthcare officially announced the completion of its Series A financing round, raising tens of millions of RMB. The funds will be used to advance the construction of its oncology database service platform and the research and development of its digital health product pipeline. This investment was jointly made by Sinopharm Zhongjin Medical Industry Innovation Investment Fund, under Sinopharm Zhongjin Capital, and Xiya Si Fund. Point Stone Capital served as the exclusive financial advisor.
Wise Healthcare, established in 2018, is a leading provider of oncology big data services in China. Leveraging its real-world oncology big data platform, developed over five years, the company provides clinical research services based on a real-world study framework for pharmaceutical and medical device enterprises. Additionally, it offers a series of AI-driven digital therapeutics for oncology, built upon China’s oncology diagnosis and treatment data system and cutting-edge innovative diagnostic and therapeutic solutions, to healthcare institutions and patients.
In China, cancer incidence remains persistently high and continues to rise year by year. According to World Health Organization data, there were 4.57 million new cancer cases in China in 2020, making it the country with the highest number of new cases globally. On the other hand, compared with developed regions, there is substantial room for improvement in China’s level of cancer treatment. The five-year survival rates for many cancers in China—such as liver cancer, prostate cancer, testicular cancer, cutaneous melanoma, lymphoma, and leukemia—are far lower than those in developed countries in Europe and the United States. As one of the diseases with high incidence and high mortality in contemporary society, cancer has always been among the most complex fields in medicine and the most reliant on technological empowerment. Due to the lack of sufficiently effective, systematic clinical data to support the research and development and industrialization of innovative therapies, oncology-related scientific research and clinical treatment face numerous challenges. China still has a considerable way to go before achieving the systematic and standardized cancer prevention, diagnosis, and treatment seen in developed countries.
Wise Healthcare specializes in the construction and application development of oncology-specific disease databases. Committed to empowering improvements in cancer treatment through high-value data, the company provides closed-loop digital oncology products and service solutions for pharmaceutical and medical device companies, patients, and healthcare institutions. Since its inception, Wise Healthcare has partnered with the Chinese Society of Clinical Oncology (CSCO) to launch the China Liver Cancer Study (CLCS), a public welfare real-world study project focused on building the world’s largest liver cancer-specific database. To date, this project has engaged over 5,000 core experts, collected diagnostic, treatment, and prognostic data from more than 250,000 cancer patients, and included participation from over 100 major hospitals. In addition to liver cancer, the company is simultaneously developing specialized databases for other malignancies, including cholangiocarcinoma, pancreatic cancer, and gastric cancer. Leveraging its unique and professional oncology-specific databases, Wise Healthcare has helped medical institutions and researchers in the field produce multiple research outcomes with international impact, assisting domestic clinical experts in exploring and validating innovative diagnostic and therapeutic approaches. The company also serves numerous oncology pharmaceutical companies by conducting real-world studies and providing market insights for innovative products. Wise Healthcare’s real-world research capabilities have risen to the industry’s top tier, maintaining long-term collaborations with many leading industry associations/societies and renowned pharmaceutical companies both domestically and internationally.
With the deepening advancement of data empowerment, Wise Healthcare has developed digital therapeutics products in this field. Digital therapeutics are software-driven, evidence-based intervention programs used to treat, manage, and prevent diseases. Building on this foundation, Wise Healthcare will establish an intelligent health management system for patients, spanning from short-term oncology treatment management to long-term comprehensive disease-course care, thereby facilitating precise prevention, control, and treatment for patients.
The success of this financing round will empower Wise Healthcare to further strengthen its real-world study data service system, achieving more comprehensive coverage of patient populations and tumor types in oncology diagnosis and treatment. As the specialized oncology database expands, data-driven AI enablement will continue to enhance the efficiency of research and development for healthcare institutions and innovative pharmaceutical and medical device companies. Furthermore, AI-powered digital therapeutics products, built upon an evidence-based medicine framework, will provide scientific and advanced solutions for disease diagnosis, treatment, and management to patients in China. The company will develop a systematic and intelligent product portfolio in the fields of real-world studies and digital therapeutics, contributing to the improvement of oncology care standards in China.
Zhu Hong, founder of Wise Healthcare, has a background in bioinformatics and possesses years of academic, industry, and commercialization experience and resources in the medical big data sector. He has spearheaded long-term strategic collaborations with top oncology societies, including the Chinese Society of Clinical Oncology (CSCO) and the China Anti-Cancer Association (CACA). By jointly establishing a specialized disease information database for Chinese cancer patients, these initiatives aim to support academic research and promotion for physicians and pharmaceutical/medical device companies, while providing patients with digital therapeutic products for health management, early diagnosis, and rehabilitation assistance, thereby enhancing the standard of diagnosis and treatment in this field.
Regarding the success of this round of financing, Mr. Zhu Hong stated“Thank you to Sinopharm Zhongjin for its recognition and strategic investment in the Wise Healthcare team. Wise Healthcare will establish a R&D and service team that sets an industry benchmark in the construction and application of specialized oncology databases. By deeply cultivating the oncology niche market, we will provide clinical and AI solutions based on medical data for scientific research, diagnosis, and treatment within China’s oncology sector, thereby making greater contributions to the whole-course health management of cancer patients.”
Mr. Li Ke, General Manager of Sinopharm Zhongjin, stated:“Sinopharm Zhongjin Capital focuses on the healthcare sector and has actively invested in leading digital health companies that effectively address pain points in pharmaceutical R&D and product commercialization. There are significant development opportunities for digitalization within China’s pharmaceutical and healthcare industry. The demand for systematic real-world clinical data is most urgent for the innovative product development targeting cancer, one of the most challenging diseases to conquer. Over the past five years, the Wise Healthcare team has continuously deepened its expertise, creating multiple benchmark oncology database products for the industry and providing high-quality real-world study services to numerous innovative pharmaceutical and medical device companies. Sinopharm Zhongjin Capital will actively facilitate collaboration between Wise Healthcare and subsidiaries under Sinopharm Holding, leveraging industrial resources to help Wise Healthcare continuously enhance its oncology big data products and service portfolio, thereby contributing value to the scientific treatment of cancer patients in China.”
The Sinopharm CICC Medical Industry Innovation Investment Fund is managed by Sinopharm CICC (Shanghai) Private Equity Fund Management Co., Ltd. The fund primarily invests in high-quality enterprises in fields such as innovative medical devices, innovative drugs, innovative medical services, and new models of pharmaceutical distribution.
Sinocare CICC (Shanghai) Equity Investment Fund Partnership (Limited Partnership), managed by Sinopharm CICC (Shanghai) Private Equity Investment Management Co., Ltd., primarily invests in high-quality enterprises in the fields of artificial intelligence, the Internet of Things, enterprise services, and healthcare.
Sinopharm-CICC was established as a joint venture by Sinopharm Group Co., Ltd., the leading enterprise in China’s medical industry distribution sector, and CICC Capital, the private equity investment platform under China International Capital Corporation (CICC). Aligned with Sinopharm’s strategic objectives, Sinopharm-CICC leverages Sinopharm’s extensive resources in the healthcare industry and combines them with CICC’s robust capital strengths. By harnessing the team’s professional expertise in investment and capital integration, the company invests in high-quality enterprises in fields such as innovative medical devices, innovative drug research and development, innovative healthcare services, and new models of pharmaceutical distribution.